| Private Placement / Financing Transactions
AltruBio: The company raised an estimated $225 million of Series B venture funding in a deal led by BVF Partners on May 21, 2024. Soleus Capital, Blackstone, aMoon Fund, RA Capital Management, Cormorant Asset Management, Delos Capital Partners and other undisclosed investors also participated in the round. The company is a developer of an antibody therapeutics platform designed to assist in the treatment of cancer and immune-related inflammatory diseases.
Grey Wolf Therapeutics: The company raised GBP 99 million of Series B venture funding in a deal led by Pfizer Ventures, Intermediate Capital Group and Earlybird Venture Capital on May 23, 2024. Andera Partners, British Patient Capital, Canaan Partners, Oxford Science Enterprises, and other undisclosed investors also participated in the round. The company is a developer of a drug discovery platform intended to offer immune-oncology therapies.
Pheon Therapeutics: The company raised $120 million of Series B venture funding in a deal led by TCG Crossover Management on May 21, 2024. LightSpeed, Research Corporation Technologies, Brandon Capital, Atlas Venture, BVF Partners, Forbion and Perceptive Advisors also participated in the round. The company is a developer of Antibody-Drug Conjugate (ADC) intended for a wide range of hard-to-treat cancers.
Resilience: The company raised $25 million of venture funding in a deal led by Picus Capital and Red River West on May 21, 2024. Singular., Cathay Innovation and Seaya Ventures also participated in the round. The company is a developer of a remote patient care tech platform intended to help cancer treatment institutes as well as cancer patients during the treatment regimen.
NeraCare: The company raised an estimated EUR 20 million of Series A venture funding in a deal led by MIG AG on May 23, 2024. Synvie and BayBG Venture Capital also participated in the round. The company is a developer of a diagnostic multi-gene expression test designed to predict the course of skin cancer disease.
SamaCare: The company raised $16.7 million of Series B venture funding in a deal led by Questa Capital on May 21, 2024, putting the company’s pre-money valuation at $53.3 million. South Park Commons, Vive Collective and other undisclosed investors also participated in the round. The company is a developer of a prior authorization tool designed to reduce administrative burdens.
YGION Biomedical: The company raised EUR 15 million of Series A venture funding from undisclosed investors on May 21, 2024. The company is a developer of precision cancer therapies designed to develop a new generation of individualized neoantigen-based cancer vaccines.
Vaxess Technologies: The company raised $12 million of venture funding from Mission BioCapital, Engine Ventures and RA Capital Management on May 22, 2024. Global Health Investment Corporation also participated in the round. The company is a developer of novel therapies designed to help in oncology care and infectious diseases.
Sania Therapeutics: The company raised $5 million of venture funding from undisclosed investors on May 20, 2024. The company is a developer of gene therapies intended to improve the quality of life of people with dysfunctional neural circuits.
Enrich Biosystems: The company raised $3 million of venture funding from undisclosed investors on May 20, 2024. The company is a developer of a novel single-cell isolation technology designed to enhance biomedical research at a single-cell level.
Sunflower Therapeutics: The company raised $2 million of venture funding in the form of SAFE notes from undisclosed investors on May 24, 2024. The company is an operator of a biotechnology business intended to deliver protein manufacturing solutions.
Crio: The company received an undisclosed amount of development capital from The Riverside Company on May 21, 2024. The company is a developer of an e-source system designed to digitally track and store clinical research source data.
|
